OBSV News and Press, ObsEva SA From 11/04/21

CFRA has upgraded shares of Syneos Health (SYNH +2.9%) to buy from hold citing a "strong demand environment for CROs with its robust pipeline." The firm has a $108 price target (8% upside). Analyst Sel Hardy writes that Syneos' recent acquisitions of StudyKIK and RxDataScience allow the compa...

ObsEva (NASDAQ:OBSV): Q3 GAAP EPS of $0.01 beats by $0.23. Revenue of $20.1M Press Release As of September 30, 2021, ObsEva had cash and cash equivalents of $62.9M, compared with $31.2M as of December 31, 2020. For further details see: ObsEva EPS beats by $0.23

- Linzagolix f or uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway - - Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21 - - Ebopi...

ObsEva (NASDAQ:OBSV) announces departure of current Chief Financial Officer David Renas for personal reasons, effective January 5, 2022. Company has retained an executive search firm to assist the company’s Board of Directors with identifying a new CFO. For further det...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 29, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health,...

- Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland October 20 , 2021 – O...

– Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagoli x for the treatment of severe adenomyosis – GENEVA, Switzerland O...

ObsEva Announce s Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids- - Financing agre...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the last two weeks, Shiba Inu (CCC: SHIB-USD ) has delivered nearly threefold returns. Now, several other altcoins have the potential to see huge gains as the cryptocurrency space heats up again. However, the c...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’...